These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 31046702

  • 1. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China.
    Li X, Ding H, Geng W, Liu J, Jiang Y, Xu J, Zhang Z, Shang H.
    BMC Infect Dis; 2019 May 02; 19(1):373. PubMed ID: 31046702
    [Abstract] [Full Text] [Related]

  • 2. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.
    Pediatrics; 2002 Feb 02; 109(2):E25. PubMed ID: 11826235
    [Abstract] [Full Text] [Related]

  • 3. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L, Pan X, Dou Z, Huang P, Zhou X, Peng Z, Zheng J, Zhang J, Yang J, Xu Y, Jiang J, Chen L, Jiang J, Wang N.
    PLoS One; 2016 Feb 02; 11(2):e0148915. PubMed ID: 26900702
    [Abstract] [Full Text] [Related]

  • 4. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group.
    Clin Infect Dis; 2005 Jun 15; 40(12):e101-9. PubMed ID: 15909251
    [Abstract] [Full Text] [Related]

  • 5. An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy.
    Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR.
    Clin Infect Dis; 2011 Nov 15; 53(9):952-60. PubMed ID: 21946189
    [Abstract] [Full Text] [Related]

  • 6. The predictive role of CD4+ cell count and CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients receiving antiretroviral therapy: an eight-year observation in China.
    Li CX, Li YY, He LP, Kou J, Bai JS, Liu J, Tian B, Cao LJ, Wang KH, Kuang YQ.
    BMC Immunol; 2019 Aug 28; 20(1):31. PubMed ID: 31455209
    [Abstract] [Full Text] [Related]

  • 7. Association of Body Composition and Other Clinical Factors with Incomplete Immune Response after Highly Active Antiretroviral Therapy.
    Sun PT, Yu W, Li TS, Lin Q, Guo FP, Zhou XH, Du GY, Xu Y, Guan WM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug 20; 39(4):459-464. PubMed ID: 28877821
    [Abstract] [Full Text] [Related]

  • 8. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
    Sterling TR, Chaisson RE, Moore RD.
    AIDS; 2001 Nov 23; 15(17):2251-7. PubMed ID: 11698698
    [Abstract] [Full Text] [Related]

  • 9. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort.
    Rudy BJ, Lindsey JC, Flynn PM, Bosch RJ, Wilson CM, Hughes ME, Douglas SD, Pediatric Aids Clinical Trials Group 381 Study Team.
    AIDS Res Hum Retroviruses; 2006 Mar 23; 22(3):213-21. PubMed ID: 16545007
    [Abstract] [Full Text] [Related]

  • 10. High baseline body mass index predicts recovery of CD4+ T lymphocytes for HIV/AIDS patients receiving long-term antiviral therapy.
    Zhu J, Huang H, Wang M, Zhang Y, Mo J, Tian W, Tan S, Jiang L, Meng Z, Qin S, Ning C.
    PLoS One; 2022 Mar 23; 17(12):e0279731. PubMed ID: 36584083
    [Abstract] [Full Text] [Related]

  • 11. HIV DNA and immune alteration during successful HAART.
    Mamadou D, Yu-Huang Z, Xia C, Bo H, Hua-Ying Z, Yan H, Zi C, Qing L, Li-Wen Z, Mei H, Yun-Hai Y, Demba S, Aldebert D, Souleymane M.
    Curr HIV Res; 2013 Jun 23; 11(4):255-62. PubMed ID: 23822818
    [Abstract] [Full Text] [Related]

  • 12. Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients.
    Tedaldi EM, Brooks JT, Weidle PJ, Richardson JT, Baker RK, Buchacz K, Moorman AC, Wood KC, Holmberg SD, HOPS Investigators.
    J Acquir Immune Defic Syndr; 2006 Sep 23; 43(1):35-41. PubMed ID: 16885779
    [Abstract] [Full Text] [Related]

  • 13. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 14. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.
    Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D.
    AIDS; 2004 Oct 21; 18(15):2029-38. PubMed ID: 15577624
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status.
    van Rossum AM, Scherpbier HJ, van Lochem EG, Pakker NG, Slieker WA, Wolthers KC, Roos MT, Kuijpers JH, Hooijkaas H, Hartwig NG, Geelen SP, Wolfs TF, Lange JM, Miedema F, de Groot R, Dutch Study Group for Children with HIV Infections.
    AIDS; 2001 Nov 23; 15(17):2267-75. PubMed ID: 11698700
    [Abstract] [Full Text] [Related]

  • 16. Immune reconstitution in HIV+ subjects on lopinavir/ritonavir-based HAART according to the severity of pre-therapy CD4+.
    Marchetti G, Merlini E, Sinigaglia E, Iannotti N, Bai F, Savoldi A, Tincati C, Carpani G, Bini T, Arminio Monforte A.
    Curr HIV Res; 2012 Oct 23; 10(7):597-605. PubMed ID: 22716104
    [Abstract] [Full Text] [Related]

  • 17. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.
    Antivir Ther; 2004 Oct 23; 9(5):713-9. PubMed ID: 15535408
    [Abstract] [Full Text] [Related]

  • 18. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
    Piriou E, Jansen CA, van Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D.
    J Immunol; 2005 Aug 01; 175(3):2010-7. PubMed ID: 16034146
    [Abstract] [Full Text] [Related]

  • 19. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P, Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).
    HIV Med; 2005 May 01; 6(3):198-205. PubMed ID: 15876287
    [Abstract] [Full Text] [Related]

  • 20. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC.
    HIV Med; 2006 Mar 01; 7(2):99-104. PubMed ID: 16420254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.